UK sets aside £248m to “digitise” NHS diagnosticsThe UK government has announced £248 million in spending over the next year for a project to make Share XUK sets aside £248m to “digitise” NHS diagnosticshttps://pharmaphorum.com/news/uk-sets-aside-248m-to-digitise-nhs-diagnostics/
Early detection of cancers will require blood sweat and tearsAn NHS study of a new cancer blood test holds huge promise, but will not be without its Share XEarly detection of cancers will require blood sweat and tearshttps://pharmaphorum.com/r-d/galleri-test-nhs-early-detection-cancers/
UK study raises hopes of long COVID test within monthsA diagnostic test to detect long COVID could be available within six to 12 months, following the discovery Share XUK study raises hopes of long COVID test within monthshttps://pharmaphorum.com/news/uk-study-raises-hopes-of-long-covid-test-within-months/
Can your typing patterns reveal if you have Alzheimer’s?The neuroQWERTY technology can analyse people’s typing for signs of motor conditions like Parkinson’s disease – and now Share XCan your typing patterns reveal if you have Alzheimer’s?https://pharmaphorum.com/views-and-analysis/can-your-typing-patterns-reveal-if-you-have-alzheimers/
Roche expands COVID testing portfolio with $1.8bn GenMark dealRoche has said it will pay $1.8 billion for molecular testing company GenMark, boosting the Swiss company’s diagnostic Share XRoche expands COVID testing portfolio with $1.8bn GenMark dealhttps://pharmaphorum.com/news/roche-expands-covid-testing-portfolio-with-1-8bn-genmark-deal/
What HCPs think about COVID-19’s impact on cancerCOVID-19’s knock-on effect on cancer patients is of concern by HCPs, with delayed or decreased diagnosis seen as Share XWhat HCPs think about COVID-19’s impact on cancerhttps://pharmaphorum.com/views-analysis-oncology/what-hcps-think-about-covid-19s-impact-on-cancer-diagnosis-and-treatment/
Exact Sciences buys cancer detection company Thrive for $2.15 billionStocks for Exact Sciences leaped 33% after it announced the acquisition of liquid biopsy rival Thrive and UK Share XExact Sciences buys cancer detection company Thrive for $2.15 billionhttps://pharmaphorum.com/news/exact-sciences-buys-early-cancer-detection-company-thrive-for-2-15-billion/
COVID-19 tests prop up Roche as US biosimilars bite in Q3Roche’s pharmaceutical revenues have been hit by falling sales in its pharma division in Q3 but a spike Share XCOVID-19 tests prop up Roche as US biosimilars bite in Q3https://pharmaphorum.com/news/us-biosimilars-bite-into-roches-pharma-revenues/
Roche working “around the clock” to tackle UK test supply problemsSupplies of swabs for coronavirus and other critical NHS tests for diseases like cancer, diabetes and heart disease Share XRoche working “around the clock” to tackle UK test supply problemshttps://pharmaphorum.com/news/roche-working-around-the-clock-to-tackle-uk-test-problems/
